Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Targeted Oncology
Volume 12, Issue 6, Pages 795-803
Publisher
Springer Nature
Online
2017-08-03
DOI
10.1007/s11523-017-0522-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
- (2016) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study
- (2016) Adam Doyle et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Changing epidemiology of hepatocellular carcinoma in Asia
- (2015) George Boon-Bee Goh et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
- (2015) Amit G. Singal et al. Clinical Gastroenterology and Hepatology
- Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
- (2015) Naoshi Nishida et al. DIGESTIVE DISEASES
- Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
- (2015) Giovan Giuseppe Di Costanzo et al. Future Oncology
- Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma
- (2015) Haruhiko Takeda et al. HEPATOLOGY RESEARCH
- Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials
- (2015) Yu-Yun Shao et al. ONCOLOGY
- Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis
- (2015) Guangchao Cao et al. MEDICAL SCIENCE MONITOR
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
- (2014) Ole-Petter R. Hamnvik et al. CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy
- (2014) Noriyuki Akutsu et al. International Journal of Clinical Oncology
- Incidence and Risk of Sorafenib-Induced Hypertension: A Systematic Review and Meta-Analysis
- (2014) Yan Li et al. Journal of Clinical Hypertension
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma
- (2014) Songlin Peng et al. PLoS One
- Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
- (2014) Masayoshi Yada WORLD JOURNAL OF GASTROENTEROLOGY
- Meta-analysis of the Efficacy of Sorafenib for Hepatocellular Carcinoma
- (2013) Zhao Wang et al. Asian Pacific Journal of Cancer Prevention
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
- (2013) T Funakoshi et al. JOURNAL OF HUMAN HYPERTENSION
- Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2013) Ju-Yeon Cho et al. LIVER INTERNATIONAL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib
- (2012) Marcus A. Wörns et al. DIGESTIVE AND LIVER DISEASE
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
- (2012) Ann-Lii Cheng et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
- (2012) Xin Zhang et al. Hepatobiliary & Pancreatic Diseases International
- Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma
- (2012) Dominik Bettinger et al. HEPATOLOGY
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma
- (2012) Ronald Koschny et al. ONCOLOGY
- Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
- (2011) F Di Fiore et al. BRITISH JOURNAL OF CANCER
- Meta-analysis of dermatological toxicities associated with sorafenib
- (2011) L. Zhang et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- A single center experience of sorafenib in advanced hepatocellular carcinoma patients
- (2011) Tianqiang Song et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
- (2010) Masao Omata et al. Hepatology International
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor
- (2009) B. I. Levy ANNALS OF ONCOLOGY
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
- (2008) David Chu et al. ACTA ONCOLOGICA
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation